The prevalence of HIV infection is high in women of childbearing age in sub-Saharan Africa but, due to efficient health policies that expanded lifelong access to antiretroviral treatment in the past decade, the number of cases of pediatric HIV is constantly decreasing [
1]. However, as a consequence, the number of infants born from women living with HIV who do not acquire the infection (HIV-exposed uninfected, HEU) has increased by more than half a million between 2018 and 2020 in the region [
1]. HEU children are at an increased risk of morbidity, especially due to infectious causes, and have a 2–threefold higher mortality rate compared to their counterparts not exposed to HIV [
2,
3]. This increased vulnerability is probably correlated to maternal HIV infection since, despite optimal antiretroviral therapy (ART), the functional immunological defects caused by HIV can not be completely reversed [
4]. The maternal IgG transplacental transfer can have a crucial role in modulating the immune system of the infants and in protecting them from infections during the first 3–6 months of life, when infants have to rely only on maternal-derived immunoglobulins because of the inability to synthesize their own. Hypergammaglobulinemia, which is common in African mothers living with HIV [
5,
6] has a significant impact on IgG transfer from the mother to the fetus [
7]. Although the underlying mechanisms are not fully elucidated, it has been suggested that IgG levels over 15 g/l can cause the saturation of FcRN receptors, which mediate the IgG transplacental passage [
8], and indeed, in clinical studies, maternal IgG levels over 15 g/l have been associated with abnormal IgG concentrations in HEU infants [
9,
10]. Impairments of IgG transfer in HEU infants have been observed by some authors [
5,
11‐
14], but others reported similar IgG levels in HIV-exposed and -unexposed infants [
15,
16], or described a differential IgG passage depending on the characteristics of pathogen-specific antibodies [
14]. The difficulty to obtain consistent results can be due to different causes, such as the timing of blood sampling (most of the mother/infant pairs studies have used cord blood whose composition mostly reflect fetal rather than neonatal condition [
17]), or the lack of reference levels in healthy African infants. Moreover, IgG subclasses structures, glycosylation patterns, and polymorphisms are all factors potentially affecting transplacental passage [
18,
19]. In a previous study, we reported the dynamic development of IgG in HEU infants from 1 to 24 months, finding abnormalities in concentrations and subclasses distribution. In particular, we observed persistently low IgG2 levels, but the lack of a proper control group and of long-term antiretroviral therapy of the mothers (the study was performed in the pre-Option B + era), prevented us to draw definite conclusions [
20].
In the present study, we aimed to compare the total IgG levels and subclasses profile in two groups of 6-week old infants living in Malawi, one including HIV-exposed uninfected infants born from antiretroviral treated-mothers (HEU group) and one represented by infants born to HIV-negative mothers (HIV-unexposed, uninfected, or HUU group). Also, because of the potential impact on the development of pneumonia in these infants, we assessed the transplacental transfer of anti-Streptococcus pneumoniae total IgG and IgG2 subclass (generally considered associated with protection).